BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 12846810)

  • 21. Secondary genomic rearrangements involving immunoglobulin or MYC loci show similar prevalences in hyperdiploid and nonhyperdiploid myeloma tumors.
    Gabrea A; Martelli ML; Qi Y; Roschke A; Barlogie B; Shaughnessy JD; Sawyer JR; Kuehl WM
    Genes Chromosomes Cancer; 2008 Jul; 47(7):573-90. PubMed ID: 18381641
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma.
    Chesi M; Bergsagel PL; Shonukan OO; Martelli ML; Brents LA; Chen T; Schröck E; Ried T; Kuehl WM
    Blood; 1998 Jun; 91(12):4457-63. PubMed ID: 9616139
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mutually exclusive cyclin-dependent kinase 4/cyclin D1 and cyclin-dependent kinase 6/cyclin D2 pairing inactivates retinoblastoma protein and promotes cell cycle dysregulation in multiple myeloma.
    Ely S; Di Liberto M; Niesvizky R; Baughn LB; Cho HJ; Hatada EN; Knowles DM; Lane J; Chen-Kiang S
    Cancer Res; 2005 Dec; 65(24):11345-53. PubMed ID: 16357141
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Illegitimate switch recombinations are present in approximately half of primary myeloma tumors, but do not relate to known prognostic indicators or survival.
    Ho PJ; Brown RD; Pelka GJ; Basten A; Gibson J; Joshua DE
    Blood; 2001 Jan; 97(2):490-5. PubMed ID: 11154227
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Insertion of excised IgH switch sequences causes overexpression of cyclin D1 in a myeloma tumor cell.
    Gabrea A; Bergsagel PL; Chesi M; Shou Y; Kuehl WM
    Mol Cell; 1999 Jan; 3(1):119-23. PubMed ID: 10024885
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Frequency and distribution of trisomy 11 in multiple myeloma patients: relation with overexpression of CCND1 and t(11;14).
    Guglielmelli T; Giugliano E; Cappia S; Papotti M; Saglio G
    Cancer Genet Cytogenet; 2007 Feb; 173(1):51-6. PubMed ID: 17284370
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular Pathogenesis of Multiple Myeloma: Clinical Implications.
    Maura F; Bergsagel PL
    Hematol Oncol Clin North Am; 2024 Apr; 38(2):267-279. PubMed ID: 38199896
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transvection mediated by the translocated cyclin D1 locus in mantle cell lymphoma.
    Liu H; Huang J; Wang J; Jiang S; Bailey AS; Goldman DC; Welcker M; Bedell V; Slovak ML; Clurman B; Thayer M; Fleming WH; Epner E
    J Exp Med; 2008 Aug; 205(8):1843-58. PubMed ID: 18625744
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alterations of the cyclin D1/pRb/p16(INK4A) pathway in multiple myeloma.
    Krämer A; Schultheis B; Bergmann J; Willer A; Hegenbart U; Ho AD; Goldschmidt H; Hehlmann R
    Leukemia; 2002 Sep; 16(9):1844-51. PubMed ID: 12200702
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential positioning and close spatial proximity of translocation-prone genes in nonmalignant B-cells from multiple myeloma patients.
    Martin LD; Harizanova J; Zhu G; Righolt CH; Belch AR; Mai S; Pilarski LM
    Genes Chromosomes Cancer; 2012 Aug; 51(8):727-42. PubMed ID: 22489023
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selective usage of D-type cyclins in lymphoid malignancies.
    Suzuki R; Kuroda H; Komatsu H; Hosokawa Y; Kagami Y; Ogura M; Nakamura S; Kodera Y; Morishima Y; Ueda R; Seto M
    Leukemia; 1999 Sep; 13(9):1335-42. PubMed ID: 10482983
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma.
    Bergsagel PL; Chesi M; Nardini E; Brents LA; Kirby SL; Kuehl WM
    Proc Natl Acad Sci U S A; 1996 Nov; 93(24):13931-6. PubMed ID: 8943038
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The enigma of ectopic expression of FGFR3 in multiple myeloma: a critical initiating event or just a target for mutational activation during tumor progression.
    Chesi M; Bergsagel PL; Kuehl WM
    Curr Opin Hematol; 2002 Jul; 9(4):288-93. PubMed ID: 12042702
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of kinetin riboside as a repressor of CCND1 and CCND2 with preclinical antimyeloma activity.
    Tiedemann RE; Mao X; Shi CX; Zhu YX; Palmer SE; Sebag M; Marler R; Chesi M; Fonseca R; Bergsagel PL; Schimmer AD; Stewart AK
    J Clin Invest; 2008 May; 118(5):1750-64. PubMed ID: 18431519
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies.
    Avet-Loiseau H; Li JY; Facon T; Brigaudeau C; Morineau N; Maloisel F; Rapp MJ; Talmant P; Trimoreau F; Jaccard A; Harousseau JL; Bataille R
    Cancer Res; 1998 Dec; 58(24):5640-5. PubMed ID: 9865713
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evidence of a role for the novel zinc-finger transcription factor ZKSCAN3 in modulating Cyclin D2 expression in multiple myeloma.
    Yang L; Wang H; Kornblau SM; Graber DA; Zhang N; Matthews JA; Wang M; Weber DM; Thomas SK; Shah JJ; Zhang L; Lu G; Zhao M; Muddasani R; Yoo SY; Baggerly KA; Orlowski RZ
    Oncogene; 2011 Mar; 30(11):1329-40. PubMed ID: 21057542
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular classification of multiple myeloma: a distinct transcriptional profile characterizes patients expressing CCND1 and negative for 14q32 translocations.
    Agnelli L; Bicciato S; Mattioli M; Fabris S; Intini D; Verdelli D; Baldini L; Morabito F; Callea V; Lombardi L; Neri A
    J Clin Oncol; 2005 Oct; 23(29):7296-306. PubMed ID: 16129847
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Cyclins D in regulation and dysregulation of the cell cycle in multiple myeloma].
    Kubiczková L; Dúcka M; Sedlaříková L; Kryukov F; Hájek R; Ševčíková S
    Klin Onkol; 2013; 26(5):313-8. PubMed ID: 24107152
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cell cycle analysis and expression of cell cycle regulator genes in myeloma cells overexpressing cyclin D1.
    Yata K; Sadahira Y; Otsuki T; Sakaguchi H; Isozaki Y; Uno M; Kurebayashi J; Fujii T; Eda S; Ueki A; Yawata Y; Yamada O; Sugihara T
    Br J Haematol; 2001 Sep; 114(3):591-9. PubMed ID: 11552984
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MMSET: role and therapeutic opportunities in multiple myeloma.
    Xie Z; Chng WJ
    Biomed Res Int; 2014; 2014():636514. PubMed ID: 25093175
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.